FOXA1 mutations in Lobular Breast Cancer: Reprogramming Responses to Tamoxifen
Prof D Heery, Dr S Johnston
Applications accepted all year round
Tumours of the breast are often hormone-dependent, meaning their growth is driven by steroid hormones such as estrogen. This hormone acts upon the estrogen receptor (ER), which together with other transcription factors such as FOXA1 drives tumour growth.
Defining the role of mitochondrial dysfunction in therapy resistance in KRAS mutant colorectal cancer models
Centre for Cancer Research and Cell Biology
Dr E Kerr, Prof I Mills, Dr M Wilson
20 January 2019
Mutant KRAS driven metabolic reprogramming is a key hallmark of cancer, providing the building blocks necessary to support aberrant cancer cell proliferation and is often achieved through rewiring glycolytic, mitochondrial and fatty acid metabolism, reportedly leading to mitochondrial dysfunction.